Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus MEGESTROL ACETATE.
Head-to-head clinical analysis: DELALUTIN versus MEGESTROL ACETATE.
DELALUTIN vs MEGESTROL ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Synthetic progestin with antineoplastic activity; suppresses pituitary gonadotropin secretion and exerts direct cytotoxic effects on endometrial cancer cells via binding to progesterone receptors. Also stimulates appetite through unclear mechanisms, possibly involving neuropeptide Y and inhibition of proinflammatory cytokines.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
400 mg orally once daily or 800 mg orally once daily (suspension) for appetite stimulation; 40-320 mg orally daily in divided doses for endometrial cancer.
None Documented
None Documented
Clinical Note
moderateMegestrol acetate + Digoxin
"Megestrol acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMegestrol acetate + Digitoxin
"Megestrol acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMegestrol acetate + Deslanoside
"Megestrol acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMegestrol acetate + Acetyldigitoxin
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Terminal half-life: 13-105 hours (mean ~34 hours) in adults; prolonged in hepatic impairment.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Renal: 50-79% as glucuronide conjugates; fecal: 8-30%; biliary: minor.
Category C
Category D/X
Progestin
Progestin
"Megestrol acetate may decrease the cardiotoxic activities of Acetyldigitoxin."